U.S. Markets close in 6 hrs 16 mins

Merrimack Pharmaceuticals, Inc. (MACK)


NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.3395+0.0595 (+4.6484%)
As of 9:44AM EDT. Market open.
People also watch
FOLDACHNSGYPCLDXARRY
  • I'm with Mack till the end. Come on calls make me some money
  • LIFETIME OPP..LOAD UP GUYS WHILE ITS MORE THAN DIRT CHEAP!
    ACRX (MC $98 M) ( Cash $72 M)FDA Decision on October 12 for potential Blockbuster & P3 Readout this month for another Drug = 500%++ POTENTIAL !!! Undiscovered Stock please do your own dd and realize the MEGA Potential ! Thank You

    AcelRx Pharma (ACRX)

    Market Cap $97.5 Million
    Cash: $72 Million
    Price $2.15

    Upcoming Major Milestones

    Zalviso Phase 3 Results in July 2017
    DSUVIA PDUFA Date October 12, 2017
    Zalviso NDA Resubmission in Q4 2017
    DSUVIA CHMP Opinion in 1H 2018 (EU Approval)
    Zalviso FDA approval expected in Q2 2018

    Biotech Catalyst Play: AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) ...
    https://insiderfinancial.com/biotech-catalyst-play-acelrx-pharmaceuticals-inc-nasdaqacrx

    There is one major catalyst set to hit press at some point during July and a subsequent catalyst slated for mid-October. If both come out as positive for the company, there is considerable upside potential on the cards. We are talking the potential to go from a $3 million revenues quarterly company to one targeting markets with a combined $1.5 billion in sales with just two drugs.

    There is what we are watching out for.
    So, the first catalyst, the July catalyst, derives from an ongoing phase 3 study of a drug called Zalviso.

    So that is the first catalyst; for the second one we have to move to the start of the final quarter, specifically, October.

    In parallel to Zalviso, AcelRx is also trying to get a drug called DSUVIA approved in the US. This one is also a pain drug, this time designed for the treatment of moderate-to-severe pain in a medically supervised setting. The company submitted an NDA for the asset at the end of last year and, in February this year, the FDA accepted the submission for consideration. On acceptance, the agency set a PDUFA day of October 12, 2017, meaning it will make a decision as to whether it is willing to approve the drug before or on that date.

    While Zalviso is our near-term catalyst, the DSUVIA decision probably holds more weight from a valuation perspective. Why? Because peak sales for this one are estimated at a little over $1.1 billion in the US alone. If FDA gives a green light for commercialization to the asset, therefore, the company could have a blockbuster drug on its hands. Combine that with the close to $400 million in revenues potential from Zalviso, and AcelRx could very justifiably become a multibillion-dollar biotech company before the end of the decade.

    Biotech Catalyst Play: AcelRx Pharmaceuticals Inc (NASDAQ:ACRX)
    We have had some big winners over the last month or so with our Biotech Catalyst series and here is another one to take a look at. The company is AcelRx Pharmaceuticals Inc (NASDAQ:ACRX), a junior biotechnology stock-based out of California with a ma
    insiderfinancial.com
  • Another down day for mini-mack. Dead money for a while longer. Check out VEEV cloud based life sciences software company growing 33% on both revenue and net income. Looks like a ten-bagger in a few short years......no kidding.
  • [!] Newly upgraded to now display all possible spread combinations - Option spread traders check out CreditSpreads.io, free live feed of mathematically gainful option credit spreads for the upcoming 4 weeks, sometimes including spreads for MACK! High probability option credit spreads offer a technique to invest with determined risk and the max profit gained up front. CreditSpreads.io lazer-targets exclusively the option spreads which fulfill its rigid standards for probability and profit, and contributes to continued profitability by telling you of any approaching situations that might affect the trade. www.creditspreads.io

    CreditSpreads.io
    Sustainable, high probability, defined risk stock option trading opportunities.
    www.creditspreads.io
  • Does Merrimack provide kidney cancer solutions or anything that involves the kidney's?
  • Option traders take a look at CreditSpreads.io, totally free live table of statistically gainful option credit spreads for the following four weeks, sometimes including spreads for MACK! High probability option credit spreads deliver an approach to trade with determined risk and the max profit received right away. CreditSpreads.io lazer-targets only the credit spreads which meet its rigid requirements for probability and profit, and ensures sustained profitability by alerting you of any approaching situations which may affect the trade. http://creditspreads.io

    CreditSpreads.io
    Sustainable, high probability, defined risk stock option trading opportunities.
    creditspreads.io
  • And SA track record? Non professionals paid for their opinions. Nice work if you can get it. And like weatherman no downside if your wrong.
  • Merrimack: A Special Situation With A Compelling Risk/Reward $MACK
    http://www.seekingalpha.com/article/4086084

  • Partnership , get to work...
  • Here we go $1.50 and on our way to $3.00.... after $3.00 we head for Cinco....
  • Check out ovit.
  • And exactly how long has Mack had huge potential upside?
    Err how many years longs?
  • 10-1 reverse split....stick it to the shareholders.
  • The current share price for Mack is utterly ridiculous: Just look at the facts:
    1 - 132 million shares O/S, with current short interest increased to 33 million from 24 million since the dividend.
    2 - There is $60 million in escrow for the convertible shares. It will either be paid out to extinguish the convertible notes, or if MACK wins, it will translate to a $.45/share dividend to shareholders. And if it does have to go to convert holders, then it is likely that there will be up to 9.6 million shares of stock that will need to be bought back.
    3 - Potential for $450 million in payments from Ibsen and $33 million from Baxalta for very achievable milestones ie $3.66 per share in value and likely dividends.
    4 - A runway of cash for development of 3 promising products into 2019.

    On a risk reward basis, the downside to the stock is negligible, and the upside is significant. Why would anyone be outright short this stock??? It makes no sense.......
  • proxy for shareholders meeting out !! wow.. more pay for big boys and reverse split.. amazing 60 page proxy of how they wanna get richer.. shareholders again screwed.. what a scam
  • very very bad, i posted a few months ago, securites law firms are lining up. Major class action to follow, sad for shareholders
  • hhh
  • IPSEN and SHIRE both have a currency called their stock. At $3.50 they only have to issue 14 million shares to buy us and we have $180 Million on the balance sheet and they have a $450 MM potential payout to us. Shire has an even better share price
  • Does anyone know when we can expect the outcome of the MACK/Wells Fargo Senior notes lawsuit?